Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.47 |
| ▸ | TTR | P02766 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2012036 | 0.85 | TDP1 (0.46) | MAPTPKMMAPK1TTRALOX15 | |
| SCHEMBL69019 | 0.84 | SNCA (0.55) | MAPTMAPK1TTRALOX15HSD17B10 | |
| SCHEMBL29495221 | 0.84 | MAPT (0.59) | MAPTPKMMAPK1ALOX15TDP1 | |
| SCHEMBL2536509 | 0.84 | MAPT (0.59) | MAPTPKMMAPK1ALOX15TDP1 | |
| SCHEMBL810816 | 0.82 | TDP1 (0.50) | MAPTMAPK1TTRALOX15HSD17B10 | |
| SCHEMBL4397890 | 0.82 | MAPT (0.53) | MAPTPKMMAPK1ALOX15TDP1 | |
| SCHEMBL7759334 | 0.82 | MAPT (0.53) | MAPTPKMMAPK1ALOX15TDP1 | |
| SCHEMBL30598678 | 0.82 | MAPT (0.53) | MAPTPKMMAPK1ALOX15TDP1 | |
| SCHEMBL2413345 | 0.78 | TDP1 (0.50) | MAPTMAPK1TTRALOX15HSD17B10 | |
| SCHEMBL2046172 | 0.78 | CA12 (0.46) | MAPTMAPK1TTRALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4635492-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4551212-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-116102575-B | Cyclic 2-aminopyrimidine compound and application thereof | 暨南大学 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024249642-A1 | EGFR INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024238406-A1 | FUROPYRIDINE COMPOUNDS AS P53 MUTANT STABILIZER AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024035757-A2 | TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | Wayshire Biopharm Holding Limited (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023082052-A1 | CYCLIC 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREOF | 暨南大学 | 2023-05-19 | — | — | WO | disclosed |
| CN-116102575-A | Cyclic 2-aminopyrimidine compound and application thereof | 暨南大学 | 2023-05-12 | — | — | CN | disclosed |
| WO-2012009617-A3 | METHODS, STORAGE MEDIUMS, AND SYSTEMS FOR ANALYZING PARTICLE QUANTITY AND DISTRIBUTION WITHIN AN IMAGING REGION OF AN ASSAY ANALYSIS SYSTEM AND FOR EVALUATING THE PERFORMANCE OF A FOCUSING ROUTING PERFORMED ON AN ASSAY ANALYSIS SYSTEM | LUMINEX CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| EP-1539133-B1 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| EP-1549156-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | Investigacion Y Nutricion, S.L. (ES) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004014361-A9 | AMINOCYCLOHEXENE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | GLAXO GROUP LTD (GB) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004014150-A1 | DENATURED CAROB FLOUR (DCF) WITH A LOW CONTENT OF SOLUBLE TANNINS AND SUGARS, MEANT FOR HUMAN CONSUMPTION AND PROCESS TO OBTAIN IT | INVESTIGACION Y NUTRICION, S.L. (ES) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025874-A1 | Quinazoline Derivative Salt Crystal Form, Preparation Method and Application | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SDHA, FH | MAPT 825/4885PKM 1362/4885MAPK1 1938/4885 |
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | MAPT 4448/4885PKM 4523/4885MAPK1 2560/4885 |
| US-20060040925-A1 | Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity | QARS1, NQO2, AAAS | MAPT 4662/4885PKM 4707/4885MAPK1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.